Fichtner, Miriam L.
Hoehn, Kenneth B.
Ford, Easton E.
Mane-Damas, Marina
Oh, Sangwook
Waters, Patrick
Payne, Aimee S.
Smith, Melissa L.
Watson, Corey T.
Losen, Mario
Martinez-Martinez, Pilar
Nowak, Richard J.
Kleinstein, Steven H.
O’Connor, Kevin C. http://orcid.org/0000-0002-7056-419X
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01-AI114780, R21-AI142198, R01AI104739)
NINDS (U54-NS115054)
Article History
Received: 29 September 2022
Accepted: 30 September 2022
First Online: 28 October 2022
Declarations
:
: KCO has received research support from Alexion, now part of AstraZeneca, and Viela Bio, now part of Horizon Therapeutics, and Cabaletta Bio. KCO is a consultant and equity shareholder of Cabaletta Bio. During the last two years, KCO has served as consultant/advisor for Alexion Pharmaceuticals, now part of AstraZeneca, and for Roche, and he has received speaking fees from Alexion, Roche, Genentech, Viela Bio, now part of Horizon Therapeutics, and UCB. MLF received a SPIN award from Grifols outside the submitted work and is a member of the Alexion-Akademie. KBH receives consulting fees from Prellis Biologics. SHK receives consulting fees from Peraton. ASP has received equity, research support, patent licensing and other payments from Cabaletta Bio; patent licensing payments from Novartis; and consultant fees from Janssen. SO has received patent licensing payments from Cabaletta Bio. The research of PMM and MMD at the School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences was financially supported by Apellis, Argenx, Genmab, Neurotune and Takeda. PMM is a co-inventor of the following patent: Use of effector-function-deficient antibodies for treatment of auto-immune diseases (Patent number: 9181344). These competing interests played no role in the research design, reference collection, decision to publish, or preparation of the manuscript.